CD123: A novel biomarker for diagnosis and treatment of leukemia

Mingyue Shi, Ruijun J. Su, Kamal Preet Parmar, Rahman Chaudhry, Kai Sun, Jianyu Rao, Mingyi Chen

Research output: Contribution to journalReview article

Abstract

Leukemia is a group of progressive hematologic malignancies derived from stem cells in bone marrow which causes a large number of cancer deaths. Even with treatment such as traditional chemotherapy, targeted therapy, and allogeneic stem cell transplantation (allo-HSCT), many patients suffer from relapse/refractory disease, and the overall survival is dismal. Leukemic stem cells (LSCs) are induced by gene mutations and undergo an aberrant and poorly regulated proliferation process which is involved in the evolution, relapse, and drug-resistance of leukemia. Emerging studies demonstrate that CD123, the interleukin 3 receptor alpha (IL-3Rα), is highly expressed in LSCs, while not normal hematopoietic stem cells (HSCs), and associates with treatment response, minimal residual disease (MRD) detection and prognosis. Furthermore, CD123 is an important marker for the identification and targeting of LSCs for refractory or relapsed leukemia. Anti-CD123 target-therapies in pre-clinical studies and clinical trials confirm the utility of anti-CD123 neutralizing antibody-drugs, CD3×CD123 bispecific antibodies, dual-affinity re-targeting (DART), and anti-CD123 chimeric antigen receptor-modified T-cell (CAR-T) therapies in progress. This review summarizes the most recent progress on the study of CD123 biology and the development of novel CD123-targeted therapies.

Original languageEnglish (US)
Pages (from-to)195-204
Number of pages10
JournalCardiovascular and Hematological Disorders - Drug Targets
Volume19
Issue number3
DOIs
StatePublished - 2019

Keywords

  • Anti-CD123
  • CD123
  • Hematologic malignant diseases
  • LSCs
  • Leukemia
  • Refractory/relapse

ASJC Scopus subject areas

  • Molecular Medicine
  • Hematology
  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'CD123: A novel biomarker for diagnosis and treatment of leukemia'. Together they form a unique fingerprint.

  • Cite this